TY - JOUR
T1 - Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression
AU - Mishalian, Inbal
AU - Bayuh, Rachel
AU - Levy, Liran
AU - Zolotarov, Lida
AU - Michaeli, Janna
AU - Fridlender, Zvi Gregorio
N1 - Funding Information:
Acknowledgments This study was supported by a Research Career Development Award from the Israel Cancer Research Fund, and partly by The Israel Cancer Association (Grant 20110103-B) and by the joint research fund of the Hebrew University and Hadassah Medical Center (Jerusalem, Israel).
PY - 2013/11
Y1 - 2013/11
N2 - The role and characteristics of tumor-associated neutrophils (TAN) in cancer are poorly defined. We have recently shown that TAN can have anti-tumorigenic (N1) or pro-tumorigenic (N2) functions. An interesting unanswered question is how the phenotype of TAN is influenced by the ongoing evolvement of tumor microenvironment. We therefore studied the phenotype and effects of TAN at different time points during tumor progression. We used two models of murine tumor cancer cell lines - Lewis lung carcinoma (LLC) and AB12 (mesothelioma). Neutrophils were studied at early and late stages and compared to each other and to neutrophils from bone marrow/periphery of naïve mice. Although there was no difference in the number of neutrophils entering the tumor, we found that at early stages of tumor development, neutrophils were almost exclusively at the periphery of the tumor. Only at later stages, neutrophils were also found scattered among the tumor cells. We further found that TAN from early tumors are more cytotoxic toward tumor cells and produce higher levels of TNF-α, NO and H2O2. In established tumors, these functions are down-regulated and TAN acquire a more pro-tumorigenic phenotype. In line with this phenotype, only depletion of neutrophils at later stages of tumor development inhibited tumor growth, possibly due to their central location in the tumor. Our work adds another important layer to the understanding of neutrophils in cancer by further characterizing the changes in TAN during time. Additional research on the functional role of TAN and differences between subsets of TAN is currently underway.
AB - The role and characteristics of tumor-associated neutrophils (TAN) in cancer are poorly defined. We have recently shown that TAN can have anti-tumorigenic (N1) or pro-tumorigenic (N2) functions. An interesting unanswered question is how the phenotype of TAN is influenced by the ongoing evolvement of tumor microenvironment. We therefore studied the phenotype and effects of TAN at different time points during tumor progression. We used two models of murine tumor cancer cell lines - Lewis lung carcinoma (LLC) and AB12 (mesothelioma). Neutrophils were studied at early and late stages and compared to each other and to neutrophils from bone marrow/periphery of naïve mice. Although there was no difference in the number of neutrophils entering the tumor, we found that at early stages of tumor development, neutrophils were almost exclusively at the periphery of the tumor. Only at later stages, neutrophils were also found scattered among the tumor cells. We further found that TAN from early tumors are more cytotoxic toward tumor cells and produce higher levels of TNF-α, NO and H2O2. In established tumors, these functions are down-regulated and TAN acquire a more pro-tumorigenic phenotype. In line with this phenotype, only depletion of neutrophils at later stages of tumor development inhibited tumor growth, possibly due to their central location in the tumor. Our work adds another important layer to the understanding of neutrophils in cancer by further characterizing the changes in TAN during time. Additional research on the functional role of TAN and differences between subsets of TAN is currently underway.
KW - Lung cancer
KW - Mesothelioma
KW - Tumor immunology
KW - Tumor microenvironment
KW - Tumor-associated neutrophils
UR - http://www.scopus.com/inward/record.url?scp=84888316284&partnerID=8YFLogxK
U2 - 10.1007/s00262-013-1476-9
DO - 10.1007/s00262-013-1476-9
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 24092389
AN - SCOPUS:84888316284
SN - 0340-7004
VL - 62
SP - 1745
EP - 1756
JO - Cancer Immunology, Immunotherapy
JF - Cancer Immunology, Immunotherapy
IS - 11
ER -